Immunome, Inc.

Immunome, Inc. has achieved a new 52-week high, reflecting a significant upward trend from its previous low. Despite underperforming compared to the S&P 500, the company's recent stock movement suggests a positive shift in market sentiment. Financial metrics indicate ongoing challenges, including losses and a negative debt-equity ratio.

Immunome, Inc. has achieved a new 52-week high of USD 17.32, significantly up from its low of USD 5.15. With a market capitalization of approximately USD 818 million, the company faces challenges, including a negative return on equity and no dividend offerings, as it competes in the biotechnology sector.

Immunome, Inc. has seen notable stock activity, achieving a significant increase today and over the past week. The company reported a net profit turnaround after previous losses and has high institutional holdings. Its return on capital employed has improved, alongside a decrease in raw material costs, showcasing resilience in the market.

Immunome, Inc. has achieved a new 52-week high of USD 16.40, significantly up from its low of USD 5.15. With a market capitalization of USD 818 million, the company remains loss-making and does not pay dividends, indicating ongoing challenges in the biotechnology sector despite recent stock performance improvements.

Immunome, Inc. has shown notable stock performance, gaining 16.4% on October 6, 2025, and achieving significant increases over the past week and month. Despite reporting a net profit loss for the first half of the year, the company benefits from high institutional holdings and reduced raw material costs.

Immunome, Inc. has experienced notable stock price movement, closing at $14.41 after a year marked by significant volatility, with a 52-week high of $15.12 and a low of $5.15. The company has outperformed the S&P 500 across multiple time frames, showcasing its competitive positioning in the market.

Immunome, Inc. has seen a significant rise in its stock today, contrasting with the S&P 500's minimal gain. The company reported a net profit after several quarters of losses and a decrease in raw material costs. Despite challenges over the past year, institutional holdings remain strong.

Immunome, Inc. has seen a notable rise in its stock today, reaching an intraday high and reflecting a strong weekly performance compared to the S&P 500. The company recently reported a net profit after several quarters of losses, aided by a decrease in raw material costs.

Immunome, Inc. has recently experienced a stock price increase, reflecting positive market dynamics. Technical indicators suggest a bullish sentiment, while the company's performance has significantly outpaced the S&P 500 over various periods, showcasing its resilience and potential in the biotechnology sector.

Immunome, Inc. has experienced a notable increase in stock performance, reaching an intraday high and outperforming the S&P 500 over the past day and week. Despite a year-long decline, the company reported positive results after several quarters of losses and has high institutional holdings, reflecting investor confidence.

Immunome, Inc. faced a significant stock price drop today, reaching an intraday low. Despite recent short-term gains, the company has struggled over the past year. It reported a higher net loss for the first half of the year, alongside reduced raw material costs, but continues to face financial challenges.

Immunome, Inc. has seen a significant stock price increase, outperforming the broader market recently. Despite a challenging year with a notable decline, the company reported positive results after several quarters of losses and maintains strong institutional support. Its long-term performance indicates potential resilience.